| Literature DB >> 26573174 |
Daniel J Stevens1, Natalie S Blencowe2,3, Philip J McElnay3, Rhiannon C Macefield2, Jelena Savović2, Kerry N L Avery2, Jane M Blazeby4,5.
Abstract
Unplanned general surgery represents a major workload and requires comprehensive evaluation with appropriate outcomes. This study aimed to summarize current reporting of patient-reported outcomes (PROs) in randomized clinical trials (RCTs) in unplanned general surgery. A systematic review identified RCTs reporting PROs in the commonest six areas of unplanned general surgery. Details of the PRO measures were examined using the CONSORT extension for PRO reporting in RCTs. Extracted information about each PRO domain included the reporting of baseline PROs, rationale for PRO selection and whether PRO findings were used in conjunction with clinical outcomes to inform treatment recommendations. The internal validity of included studies was assessed using the Cochrane risk of bias tool. 12,519 abstracts were screened and 20 RCTs containing data from 2037 patients included. Included studies used 14 separate PRO measures covering 35 different health domains. A visual analogue assessment of pain was most frequently reported (n = 13). Reporting of baseline PRO data was uncommon (11/35 PRO domains). The rationale for PRO data collection and a PRO-specific hypothesis were provided for 9 (25.7 %) and 5 (14.3 %) domains, respectively. Seventeen RCTs (85.0 %) used the PRO data alongside clinical outcomes to inform treatment recommendations. Of the 116 risk of bias assessments, 77 (66.0 %) were judged as high or unclear. There is a lack of well designed, and conducted RCTs in unplanned general surgery that include PROs. Future work to define relevant PROs and methods for optimal assessment are needed to inform health care decision-making.Entities:
Mesh:
Year: 2016 PMID: 26573174 PMCID: PMC4709380 DOI: 10.1007/s00268-015-3292-1
Source DB: PubMed Journal: World J Surg ISSN: 0364-2313 Impact factor: 3.352
Fig. 1Flow diagram of papers throughout the systematic review, according to PRISMA criteria [46]
Details of included studies
| All studies | |
|---|---|
| Number of participating centres | |
| Single | 10 |
| Multiple | 6 |
| Not specified | 4 |
| Median number of centres if multiple (range) | 1 (1–25) |
| Geographical region of study | |
| Asia | 7 |
| Europe | 8 |
| Middle East | 1 |
| North America | 4 |
| Diagnoses under investigation | |
| Appendicitis | 13 |
| Biliary colic/acute cholecystitis | 2 |
| Large or small bowel emergencies | 4 |
| Peptic ulcer | 1 |
| Abdominal wall hernia | 0 |
| Perianal abscess | 0 |
| Types of intervention studied | |
| Open vs. Minimally invasive surgery | 10 |
| Surgery at different time points | 4 |
| Open vs. Endoscopy and surgery | 2 |
| Components of the same surgical procedurea | 2 |
| SILSb vs. minimally invasive surgery | 1 |
| Surgery vs. conservative management | 1 |
| Inclusion/exclusion criteria | |
| Specified | 19 |
| Not specified | 1 |
| Nature of primary outcomec | |
| Mortality | 0 |
| Complications | 4 |
| Peri-operative technical outcomes | 1 |
| Treatment pathway outcomes | 2 |
| Patient-reported outcomes | 2 |
| Cost/resources | 1 |
| Not specified | 10 |
| Study participants | |
| Adults | 9 |
| Children | 1 |
| Both | 7 |
| Not specified | 3 |
| Mean number of participants (range)d | 120 (37–369) |
| IRB or ethical approval reported | 14 |
ae.g. comparing two methods of wound closure
bSingle-Incision Laparoscopic Surgery
cPrimary outcome fitted two categories therefore percentages calculated from denominator of 22
dNot reported in three of the included studies
Details of PROMs used
| All studies | |
|---|---|
| Number of PROMs used per study | |
| One | 11 (55.0) |
| Two | 6 (30.0) |
| Three or more | 3 (15.0) |
| PROMs used1 | |
| Gastrointestinal quality of life index (GIQLI) | 2 (5.7) |
| Short Form-36 (SF-36) | 3 (8.6) |
| EQ-5D | 3 (8.6) |
| Other validated PROM | 4 (11.4) |
| Visual analogue scale (pain) | 12 (34.3) |
| Visual analogue scale (cosmesis) | 2 (5.7) |
| Non-validated instrument | 9 (25.7) |
| Consent process for PRO data collection reported | 0 (0) |
| Location of PROM administration reported | 5 (25.0) |
1Calculated from total number of PROMs used in all 20 studies, n = 35
Reporting standards for PRO data [11]
| Number of PROs | |
|---|---|
| PROs identified in the abstract as a primary or secondary outcome | 9 (25.7) |
| Rationale for PRO assessment provided | 9 (25.7) |
| PRO hypothesis stated in background/objectives | 5 (14.3) |
| PROs used in eligibility/stratification criteria | 0 (0) |
| Evidence of chosen PRO instrument’s validity and reliability provided | 7 (20) |
| Reporting of the person completing the PRO: | 19 (54.3) |
| Method of data collection | |
| Paper | 13 (37.1) |
| Telephone | 1 (2.9) |
| Electronic | 0 (0) |
| Other | 1 (2.9) |
| Not reported | 20 (57.1) |
| Explicit statement of statistical approaches for dealing with missing data | 1 (2.9) |
| Baseline data collected | 11 (31.4) |
| Reporting of number of patients completing PROMs at follow-upa | 13 (13.1) |
| Additional analyses reported, included distinction between pre-specified and exploratory | 0 (0) |
| PRO-specific limitations provided | 8 (22.6) |
| PRO data interpreted alongside clinical outcomes | 27 (74.3) |
aFrom 99 follow-up time points
Risk of bias assessment [14]
| Issue | |||||||
|---|---|---|---|---|---|---|---|
| Sequence generation | Allocation concealment | Blinding (participants/personnel) | Incomplete outcome data | Blinding of outcome assessment | Selective outcome reporting | Other bias | |
| Bertleff [ | Low risk | Unclear risk | High risk | Low risk | High risk | High risk | |
| Blakely [ | Low risk | High risk | High risk | Low risk | High risk | Low risk | |
| Cheung [ | Low risk | Unclear risk | High risk | High risk | High riska | High risk | |
| Clarke [ | Unclear risk | Unclear risk | Low risk | High risk | Low risk | High risk | |
| Goudar [ | Unclear risk | Unclear risk | High risk | High risk | Unclear risk | Low risk | |
| Hansson [ | High risk | High risk | High risk | Low risk | Unclear risk | Low risk | |
| Kaplan [ | High risk | High risk | Unclear risk | Low risk | Low risk | Low risk | |
| Kargar [ | Low risk | Unclear risk | High risk | Unclear risk | High risk | High risk | |
| Klarenbeek [ | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | |
| Kouhia [ | Unclear risk | High risk | Unclear risk | Low risk | Unclear risk | Unclear risk | |
| Macafee [ | Low risk | Low risk | High risk | Low risk | High risk | Low risk | Low risk |
| Malik [ | Unclear risk | High risk | Unclear risk | Unclear risk | Unclear risk | Unclear risk | |
| Alam Jan [ | Unclear risk | High risk | High risk | High risk | High risk | Low risk | |
| Ricca [ | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Low risk |
| Schurman [ | * | * | * | * | * | * | * |
| Suresh [ | Low risk | High risk | Unclear risk | Unclear risk | Unclear risk | Unclear risk | |
| van der Wal [ | Low risk | Unclear risk | Unclear risk | Unclear risk | Unclear risk | High risk | |
| van Hooft [ | Low risk | Low risk | High risk | Low risk | Unclear risk | Low risk | |
| Yadav [ | Unclear risk | High risk | Unclear risk | Unclear risk | Unclear risk | Unclear risk | |
| Yuen Bun Teoh [ | Low risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | |
* Pilot RCT—not appropriate to assess RoB
aLow risk for mortality and high risk for all other outcomes